Briefcases -- All Litigations -- SGLT2 INHIBITORS
SGLT2 INHIBITORS
Case Files
News
Easy Button
Committees

Categories

Sort by:
  1. SGLT2 Inhibitors FDA and Other Evidence
  2. Canadian Invonaka Lawsuit
  3. SGLT2 FDA Caution May 2015
  4. SGLT2 Inhibitors Evidence
  5. About DKA Science and Evidence
  6. Johnson and Johnson Stockholder Lawsuit Re: Levaguin
  7. SGLT2 Inhibitors Dec 2015 New Black Box Warning
  8. Jaridance FDA (Intital Approval 2014)
  9. Glucotoxicity, Insulin Resistance and DKA
  10. Stroke and Heart Attack, PE and DVT in DKA
  11. How SGLT2s Work and Why they Cause DKA (Theory)
View All

Documents

Sort by:
  1. SGLT2 Inhibitors Dec 2015 Warning.pdf
  2. J & J Stock Holders RICO Re: Levaquin Complaints
  3. Stroke and Heart Attack in DKA.pdf
  4. FDA Approved SGLT2 Inhibitors
  5. Facts about Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
  6. SGLT2 Inhibitors FDA Info For Pateints
  7. SGLT2 Adverse Event Data
  8. Invonaka Lawsuit Filed in Canada.pdf
  9. Invokana Quarter Watch 2014.pdf
  10. SGLT2 Inhibitors Dec 2015 Warning.pdf
  11. Dapagliflozin improves muscle insulin but inheances endrogenous gluscose production.pdf
  12. Dehyration and the Endocrine System.pdf
  13. Dehyration and the Endocrine System.pdf
  14. SGLT2 Inhibitors Dec 2015 Warning.pdf
  15. Glucotoxicity.pdf
  16. Insulin Resistance and DKA.pdf
  17. Presumed paradoxical embolus in a patient with diabetic ketoacidosis.pdf
  18. DKA and PTE.pdf
  19. DKA and Thrombotic Complications.pdf
  20. Presumed paradoxical embolus in a patient with diabetic ketoacidosis.pdf
  21. Pulmonary Embolus Secondary to Diabetic Ketoacidosis.PDF
  22. DKA and PE.pdf
  23. Why SGLT2s cause DKA Theory.pdf
  24. How SGLT2s Work.pdf
  25. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.pdf
  26. Understanding DKA.pdf
  27. Diabetic Ketoacidosis Death Rates.pdf
  28. Diabetic ketoacidosisn complications.pdf
  29. DKA and PTE.pdf
  30. DKA and PE.PDF
  31. DKA and PTE.pdf
  32. DKA and Thrombotic Complications.pdf
  33. DKA Complications.pdf
  34. DKA in Adults.pdf
  35. DKA Management in Adults.pdf
View All
SGLT2 INHIBITORS: Sub Briefcases
Jardiance Litigation
Farxiga Litigation
Xigduo XR Litigation
Synjardy Litigation
Invokamet
Glyxambi Litigation